Gene therapy comes of age
Oxford BioMedica may have a cure for leukaemia. Its share price has soared since the last week of June. Its…
8 years ago
Equities
Was Woodford right to sell Glaxo and hold AstraZeneca?
AstraZeneca (LON:AZN) and GlaxoSmithKline (LON:GSK) are the two pharmaceutical giants of the FTSE 100. They are also both high yield…
8 years ago
2 of the best UK-focused recovery stocks
Recovery stocks can be among the most profitable investments. One reason for this is that the market usually expects disappointing…
8 years ago
3 ways to capitalise on UK housing potential
The housing market has been a profitable place to invest in the last few decades. A fundamental imbalance between supply…
8 years ago
How to profit from the aviation revolution
Things are changing in the aviation business. Three new trends in aircraft technology are about to revolutionise the industry. First,…
8 years ago
The forthcoming global cyber-war – and who will win
On 12 May this year a virulent piece of ransomware was unleashed upon the globe by persons yet unknown. In…
8 years ago
3 of the highest-yielding FTSE 100 shares
One of the major challenges facing investors is how to generate an income return which beats inflation. This has been…
8 years ago
Are these the top 3 gold stocks in London?
Gold may not have a practical value as an alternative currency. It’s not possible to enter a shop and pay…
8 years ago
The ONE ratio that reveals how expensive tech stocks really are
- FANG Stocks (Facebook, Amazon, Netflix, Google/Alphabet) have rallied a few times in the last 4-5 years. This seems to…
8 years ago
Weakening pound makes Vodafone more attractive
Since the EU referendum on 23 June 2016, the pound has weakened significantly versus a basket of major currencies. For…
8 years ago